Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGT-006
- Development stage
- Phase 2
- Lead developer
- Metagen Therapeutics
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MGT-006 is an investigational oral microbiome therapy developed by Metagen Therapeutics for the treatment of moderately active ulcerative colitis. As a live biotherapeutic product, it consists of a defined or donor-derived microbial consortium encapsulated for oral delivery, aimed at restoring intestinal dysbiosis and modulating the mucosal immune response. The drug is currently undergoing Phase 1b/2a clinical evaluation in Japan and the United States, focusing on safety, tolerability, and the successful engraftment of therapeutic bacteria within the patient's gut microbiome.
Beyond the preview
Go deeper on MGT-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGT-006.